These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27421997)

  • 61. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
    J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
    Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
    Perisano C; Vitiello R; Sgambato A; Greco T; Cianni L; Ragonesi G; Malara T; Maccauro G; Martini M
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 3):289-294. Congress of the Italian Orthopaedic Research Society. PubMed ID: 33261292
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bone versus soft-tissue sarcomas in the elderly.
    Torigoe T; Terakado A; Suehara Y; Kurosawa H; Yazawa Y; Takagi T
    J Orthop Surg (Hong Kong); 2010 Apr; 18(1):58-62. PubMed ID: 20427836
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis.
    Slater NA; Googe PB
    J Cutan Pathol; 2016 Aug; 43(8):663-70. PubMed ID: 27153517
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
    Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of newer prognostic markers for adult soft tissue sarcomas.
    Levine EA; Holzmayer T; Bacus S; Mechetner E; Mera R; Bolliger C; Roninson IB; Das Gupta TK
    J Clin Oncol; 1997 Oct; 15(10):3249-57. PubMed ID: 9336362
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
    Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
    Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
    Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma.
    Yokoyama S; Miyoshi H; Nishi T; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Kakuma T; Ohshima K
    Ann Thorac Surg; 2016 Apr; 101(4):1361-9. PubMed ID: 26794891
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
    Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
    Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
    Kelany M; Barth TF; Salem D; Shakweer MM
    Pathol Oncol Res; 2021; 27():1609804. PubMed ID: 34276259
    [No Abstract]   [Full Text] [Related]  

  • 75. Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.
    Miyake M; Oda Y; Nishimura N; Morizawa Y; Ohnishi S; Hatakeyama K; Fujii T; Hori S; Gotoh D; Nakai Y; Anai S; Torimoto K; Tsukamoto S; Fujii H; Kido A; Honoki K; Matsumura Y; Okajima E; Tanaka N; Fujimoto K
    Oncol Lett; 2020 Nov; 20(5):190. PubMed ID: 32952659
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas.
    Pollino S; Benassi MS; Pazzaglia L; Conti A; Bertani N; Righi A; Piccinni-Leopardi M; Picci P; Perris R
    Histol Histopathol; 2018 Jun; 33(6):597-608. PubMed ID: 29297565
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus.
    Bagir EK; Acikalin A; Avci A; Gumurdulu D; Paydas S
    J Clin Pathol; 2018 Jul; 71(7):637-641. PubMed ID: 29439008
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PD-1 and PD-L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics.
    Kim YJ; Jung CJ; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
    J Cutan Pathol; 2021 Feb; 48(2):221-228. PubMed ID: 32779238
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immune microenvironment of intimal sarcomas: Adaptive immune resistance with potential therapeutic implications.
    Birkness-Gartman JE; Thomas DL; Engle LL; Voltaggio L; Thompson ED
    Am J Clin Pathol; 2024 Mar; 161(3):256-263. PubMed ID: 37921094
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas.
    Dancsok AR; Setsu N; Gao D; Blay JY; Thomas D; Maki RG; Nielsen TO; Demicco EG
    Mod Pathol; 2019 Dec; 32(12):1772-1785. PubMed ID: 31263176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.